A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ficlatuzumab in Combination with Cetuximab in Participants with Recurrent or Metastatic (R/M) HPV-Negative Head and Neck S

Activity Type
Clinical Trial
Date
Dollar Amount
*
Grant Type
Contract
Principal Investigator
Ricklie Julian
Sponsor
Aveo Pharmaceuticals Incorporated
Unit
Cancer Center Division